Drug Profile

ECC 4703

Alternative Names: ECC-4703

Latest Information Update: 28 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Eccogene
Class Antihyperlipidaemics; Hepatoprotectants; Small molecules
Mechanism of Action Thyroid hormone receptor beta agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase I Dyslipidaemias
Preclinical Obesity
No development reported Non-alcoholic steatohepatitis

Most Recent Events

28 Sep 2025 No recent reports of development identified for phase-I development in Non-alcoholic-steatohepatitis(In volunteers) in USA (PO, Capsule)
17 Jun 2025 Preclinical trials in Obesity in China (PO) prior to June 2025
17 Jun 2025 Pharmacodynamics data from a preclinical study in Obesity released by Eccogene

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com